FDA Brief

Warning letters Animal

FDA warning letter to

Energetic Essences, LLC dba Pet Essences

High riskIssued Nov 12, 2024Posted Jan 7, 2025Center for Veterinary Medicine

FDA warned Pet Essences that its Seizures formula is an unapproved new animal drug marketed to treat seizures in animals.

What happened

FDA reviewed Pet Essences' website from October to November 2024 and found the firm offering a "Seizures" product for animals. The website and labeling claimed the formula reduces seizure frequency, severity, and duration, prevents seizures, and manages active seizures. FDA said these claims make it a drug, and because it lacks approval or index listing, it is an unapproved new animal drug and adulterated.

What FDA found

  1. The product is a drug because it is intended to treat seizures in animals.

    FD&C Act § 201(g)(1) [21 U.S.C. § 321(g)(1)]
  2. The product is a new animal drug because it is not generally recognized as safe and effective for its labeled use.

    FD&C Act § 201(v) [21 U.S.C. § 321(v)]
  3. To be legally marketed, a new animal drug needs FDA approval, conditional approval, or index listing.

    FD&C Act §§ 512, 571, 572 [21 U.S.C. §§ 360b, 360ccc, 360ccc-1]
  4. The product is not approved or index listed, so it is unsafe and adulterated.

    FD&C Act § 512(a) [21 U.S.C. § 360b(a)]; § 501(a)(5) [21 U.S.C. § 351(a)(5)]
  5. Introducing or delivering the unapproved drug into interstate commerce is prohibited.

    FD&C Act § 301(a) [21 U.S.C. § 331(a)]
  6. Website claims that the formula reduces, prevents, or manages seizures show the product's intended use as a drug.

    FD&C Act § 201(g)(1) [21 U.S.C. § 321(g)(1)]

What FDA wants

FDA asks Pet Essences to notify it in writing within 15 working days of the steps taken to correct the violations and prevent recurrence, with related documentation. If correction cannot be completed in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • pet product brands making disease-treatment claims
  • retailers and distributors selling pet seizure products
  • veterinarians and pet owners considering unapproved seizure treatments

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. AHC Products, Inc.

    AHC Products, Inc. was cited for manufacturing-rule violations and unapproved animal drugs, including AniPrin and Rot-B-Gone.

    High risk
  2. The Fish Aid

    FDA warned The Fish Aid it sells unapproved, unlisted antibiotics for aquarium fish and birds without veterinary oversight.

    High risk
  3. DK Hardware Supply

    FDA warns DK Hardware Supply over unapproved, unlisted aquarium-fish antibiotic drugs.

    High risk
  4. Synergy Animal Products, Inc.

    Synergy Animal Products marketed unapproved animal drugs for dairy cows with inadequate directions and major manufacturing violations.

    High risk